• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Oruka Therapeutics (ORKA) Looks Fully Priced Following Strong EVERLAST B Psoriasis Trial Data

    Simply Wall St·10/27/2026 14:16:45
    Listen to the news

    Oruka Therapeutics (ORKA) stock is reacting to fresh Week 16 data from the EVERLAST-B Phase 2b trial of psoriasis drug candidate ORKA-001, which showed dose-dependent efficacy with a safety profile comparable to existing IL-23 inhibitors.

    The reaction has been sharp. After the Week 16 readout and related calls over the past two days, Oruka Therapeutics has a 1-day share price return of 12.7% and a 7-day share price return of 21.28%, while the year-to-date share price return of 219.53% and 1-year total shareholder return of 226.1% point to strong momentum rather than a new story emerging out of nowhere.

    Capture the same kind of momentum story as Oruka Therapeutics by scanning our hand picked 34 healthcare AI stocks, which are also reshaping how complex diseases get treated.

    After a 200% plus run and a fresh pop on the EVERLAST-B readout, the question now is simple: Does Oruka Therapeutics still offer a skewed payoff for new money at US$90.33?

    Preferred Price-to-Book of 5.4x: Is It Justified?

    Valuation on Oruka Therapeutics right now hinges on its price-to-book ratio, which sits at 5.4x based on the latest figures, and that multiple is high relative to the broader US Biotechs group.

    The price-to-book, or P/B, compares Oruka Therapeutics' market value to its net assets on the balance sheet. For development stage drug makers with no meaningful revenue and ongoing losses, investors often lean on this yardstick because earnings based ratios do not apply and cash flow is hard to model with confidence.

    In Oruka Therapeutics' case, the story is mixed. The business is unprofitable, is forecast to remain loss making over the next 3 years, reports no revenue, and has relied on higher risk funding with shareholders substantially diluted in the past year. Against that backdrop, a P/B of 5.4x signals investors are paying a steep price relative to the book value for a pipeline led by ORKA-001 and ORKA-002.

    The peer comparison underlines that tension. The same 5.4x P/B that flags "good value" versus a peer subset with a 32.2x average still looks expensive compared to the wider US Biotechs industry average of 1.8x, where Oruka Therapeutics trades at roughly 3x that broader benchmark.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 5.4x (OVERVALUED)

    Still, Oruka Therapeutics faces clear pressure points, including continued losses of US$109.688 million and reliance on future trial readouts for ORKA-001 and ORKA-002.

    Find out about the key risks to this Oruka Therapeutics narrative.

    Next Steps

    If this Oruka Therapeutics story feels finely balanced to you, use that urgency to pull up the underlying data, pressure test the thesis, and then weigh the 5 important warning signs.

    Looking for more Oruka Therapeutics style opportunities?

    If Oruka Therapeutics has your attention today, do not stop at a single ticker. Broaden your watchlist and give yourself better odds of spotting the next setup.